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STATE-OF-THE-ART PAPER STATE-OF-THE-ART PAPER2615Biomaterials for the Treatment of MIAboli A. Rane, Karen L. Christman
Rane and Christman update their previous review on the potential for biomaterials as
therapeutic interventions after myocardial infarction (MI). The potential approaches include
left ventricular restraint devices, epicardial patches, and injectable therapies. The utility of left
ventricular restraints is now questioned. Epicardial patches, either cellular or noncellular,
facilitate cell-based therapies, presumably by serving as a scaffold to support cellular
differentiation and organization. Direct myocardial injections with various compounds from
fibrin to chitosan may help to reduce scar thickness and improve left ventricular function and
can be delivered percutaneously.CLINICAL RESEARCH INTERVENTIONAL CARDIOLOGY
2630CRP More Useful Than Platelet Function Assay
for Predicting Adverse Events After PCIDuk-Woo Park, Seung-Whan Lee, Sung-Cheol Yun, Hae-Geun Song, Jung-Min Ahn, Jong-Young Lee,
Won-Jang Kim, Soo-Jin Kang, Young-Hak Kim, Cheol Whan Lee, Seong-Wook Park, Seung-Jung Park
Park and colleagues investigated the clinical utility of measuring platelet reactivity and
C-reactive protein (CRP) to identify patients at increased risk of adverse events after
percutaneous coronary intervention (PCI). Almost 3,000 patients who received drug-eluting
stents (DES) were studied with a post-PCI VerifyNow P2Y12 assay and a baseline CRP
measurement. During a median follow-up of 2.2 years, there was no difference in the rates of
the primary endpoint among patients with or without high on-treatment platelet reactivity.
But patients with elevated CRP levels were at significantly higher risk compared to those
with nonelevated CRP levels. These results suggest that measuring platelet response to
clopidogrel is not useful for identifying patients at increased risk for post-PCI adverse events,
but CRP may be.
Editorial Comment: Grant W. Reed, Christopher P. Cannon, page 2640(continued on page A-28)
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EMYOCARDIAL INFARCTION2642Impact of Obesity on Outcomes for STEMI PatientsSandeep R. Das, Karen P. Alexander, Anita Y. Chen, Tiffany M. Powell-Wiley, Deborah B. Diercks,
Eric D. Peterson, Matthew T. Roe, James A. de Lemos
Das and colleagues studied the impact of extreme (Class III) obesity (body mass index [BMI]
40 kg/m2) on ST-segment elevation myocardial infarction (STEMI) care and outcomes
sing data from over 50,000 patients. A total of 5.1% of STEMI patients had Class III
besity; these patients tended to be younger, had higher rates of diabetes, hypertension, and
yslipidemia, but lower prevalence of smoking and less extensive coronary artery disease.
rocess of care measures were similar across BMI categories, but those with Class III obesity
ad significantly higher rates of risk-adjusted in-hospital mortality compared to those with
lass I obesity.ditorial Comment: Carl J. Lavie, Richard V. Milani, Hector O. Ventura, page 2651MYOCARDIAL INFARCTION2654hs-CRP Often Normal in Patients With STEMINicole Cristell, Domenico Cianflone, Alessandro Durante, Enrico Ammirati, Diego Vanuzzo, Michela Banfi,
Giliola Calori, Azeem Latib, Filippo Crea, Giancarlo Marenzi, Monica De Metrio, Luciano Moretti, Hui Li,
Neal G. Uren, Dayi Hu, Attilio Maseri
Cristell and associates sought to determine if high-sensitivity C-reactive protein (hs-CRP)
levels are useful for identifying patients at risk of ST-segment elevation myocardial infarction
(STEMI). The hs-CRP levels were determined in 887 STEMI patients with no previous
cardiac history and matched controls. Blood samples were obtained before treatment 6 h
from symptoms onset, and were found to be indicative of pre-infarction levels. Median hs-
CRP values were significantly higher in patients than controls; however 41% of patients had
hs-CRP levels 2 mg/l. A cut-off value of 2 mg/l for hs-CRP would incorrectly identify 41%
of STEMI patients as low risk.
Editorial Comment: C. Richard Conti, page 2662(continued on page A-30)
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hCONGENITAL HEART DISEASE2664Stenting May Be the Preferred Treatment for Coarctation of the AortaThomas J. Forbes, Wei Du, Dennis W. Kim, MD, Ralf Holzer, Zahid Amin, Ziyad Hijazi,
Abdolrahim Ghasemi, Jonathan J. Rome, David Nykanen, Evan Zahn, Collin Cowley, Mark Hoyer,
David Waight, Daniel Gruenstein, Alex Javois, Susan Foerster, Jacqueline Kreutzer, Nancy Sullivan,
Asra Khan, Carl Owada, Donald Hagler, Thomas Zellers, Scott Lim, Joshua Canter, and the
CCISC Investigators
Forbes and colleagues compared the safety and efficacy of surgical, stent, and balloon
angioplasty (BA) for the treatment of coarctation of the aorta. This is the first multicenter
study evaluating acute and follow-up outcomes of these 3 treatment options in children 10 kg.
total of 350 patients from 36 institutions were enrolled, but treatment allocation was not
andomized. All 3 arms showed significant improvements acutely and at follow-up in resting
ystolic blood pressure (BP) and upper to lower extremity BP gradients. Stenting had shorter
ospitalization than surgical patients and fewer complications than surgical and BA patients.
t short-term and intermediate follow-up, stent and surgical patients achieved superior
emodynamic and integrated aortic arch imaging outcomes than BA patients.GENETICS AND GENOMICS2675Genetic Risk Predictors May Be Different in DiabeticsLu Qi, Layla Parast, Tianxi Cai, Christine Powers, Ernest V. Gervino, Thomas H. Hauser,
Frank B. Hu, Alessandro Doria
Qi and colleagues evaluated whether coronary heart disease (CHD)-susceptibility loci
identified by genome-wide association studies (GWAS) of the general population also
contribute to CHD in type 2 diabetes. Five of fifteen genetic markers showed directionally
consistent associations with CHD in 3 different case-control studies. A genetic risk score
(GRS) was created by combining the risk alleles of the 5 significantly associated loci.
Individuals with GRS 8 (19% of diabetic subjects) had almost a 2-fold increase in CHD
risk compared to individuals with GRS 5 (30% of diabetic subjects). These results illustrate
the consistency and differences in the determinants of genetic susceptibility to CHD in
diabetic patients and the general populations.PRE-CLINICAL RESEARCH PRE-CLINICAL RESEARCH
2683Beta3-Adrenoreceptor Stimulation Ameliorates
Myocardial Ischemia/Reperfusion InjuryJuan P. Aragoñ, Marah E. Condit, Shashi Bhushan, Benjamin L. Predmore, Sandeep Patel,
D. Bennett Grinsfelder, Susheel Gundewar, Saurabh Jha, J. W. Calvert, Lili A. Barouch, Madhav Lavu,
Harold M. Wright, David J. Lefer
3-adrenoreceptor (AR) activation promotes endothelial nitric oxide synthase (eNOS) activity and
nitric oxide (NO) bioavailability. Arago´n and colleagues hypothesized that 3-AR agonists would
attenuate myocardial ischemia/reperfusion. Mice were subjected to 45 min of myocardial ischemia
followed by 24 h of reperfusion. Nebivolol, which is a 3-AR agonist, signficantly reduced the
extent of the infarcted area. Further testing showed that the cardioprotective effects of 3-AR
agonists are mediated by rapid eNOS and nNOS activation and increased NO bioavailability.Editorial Comment: Gerd Heusch, page 2692
